Antibe Therapeutics Inc(Pre-Merger) ATBPF

Healthcare

Antibe Therapeutics Inc. is a clinical-stage biotechnology company. The Company is leveraging its hydrogen sulfide (H2S) platform to develop therapies to target inflammation arising from a range of medical conditions. The Company’s pipeline includes assets that seek to overcome the gastrointestinal ulcers and bleeding associated with nonsteroidal anti-inflammatory drugs (NSAIDs). Its lead drug, otenaproxesul, is in clinical development as an alternative to opioids and NSAIDs for acute pain. Its second pipeline drug, ATB-352, is being developed for a specialized pain indication. The Company also focuses on inflammatory bowel disease (IBD). Otenaproxesul combines a moiety that releases hydrogen sulfide with naproxen, a non-steroidal, anti-inflammatory drug. ATB-352 is an H2S-releasing derivative of ketoprofen, a potent NSAID commonly prescribed for acute pain. Its IBD candidates are being designed to maintain the efficacy, safety, and pharmacokinetic properties of ATB-429.

GREY:ATBPF - Post by User

Antibe Therapeutics Inc(Pre-Merger)

Bullboard Posts

Comment by PoorOpinionon Mar 16, 2018 8:30am

139 Views

Post# 27725907

RE:What happens if only 1 person had bas side effects?

UpsidePotential wrote: Is anyone worried what could happen? What are the odds of that happening... nervous to hold my 80k position into next week.... might buy back after the news... thoughts??

Its a strategy.

The results are not garenteed. This is an experiment. The best you can say is past results suggest a positive outcome and all the work done in the proceeding years has given us the best chance for success ( I believe)

Bullboard Posts

Pro Women’s Hockey League comes to NHL 25 in December